<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199264</url>
  </required_header>
  <id_info>
    <org_study_id>ICO8ATM/2/03</org_study_id>
    <nct_id>NCT00199264</nct_id>
  </id_info>
  <brief_title>Efficacy Vulvovaginitis Candida</brief_title>
  <official_title>A Single-Blind, Randomized, Dose-Finding Study Versus Fluconazole to Assess the Efficacy and Tolerability of Five Single Doses of Albaconazole in the Treatment of Acute Non-Recurrent Candida Spp Vulvovaginitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J. Uriach and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>J. Uriach and Company</source>
  <brief_summary>
    <textblock>
      To compare the therapeutic efficacy of 10 mg, 40 mg, 80 mg, 160 mg and 320 mg of
      albaconazole, as a single oral dose, in women affected by acute non-complicated
      vulvovaginitis due to Candida spp.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, open-label, randomized study, controlled with fluconazole.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2004</start_date>
  <completion_date>October 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy VariableThe primary efficacy assessment will be carried out 24 ± 4 (FV) days following treatment or at the last patient’s.</measure>
  </primary_outcome>
  <enrollment>60</enrollment>
  <condition>Candidiasis Vulvaginitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albaconazole oral solution</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory patients over 18 years of age, with a vaginal score sum ³ 2 and KOH fresh
             examination positive for yeasts (hyphae, pseudohyphae). The diagnosis must be later
             confirmed with a positive Candida spp. culture.

        Exclusion Criteria:

          -  Patients with recurrent disease, prior treatment with antifungal agents within the
             last 7 days, immunosuppression, pregnant or lactating women, other vulvovaginal
             diseases, other systemic diseases, hypersensitivity to azole derivatives.Number of
             patients: 78 patients included to obtain 60 evaluable patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Negroni, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hosp Infecciosas F J Muñiz, Buenos Aires. Argentina</affiliation>
  </overall_official>
  <verification_date>October 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 2, 2006</last_update_submitted>
  <last_update_submitted_qc>October 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2006</last_update_posted>
  <keyword>antifungal oral therapy</keyword>
  <keyword>efficacy acute candidiasis vulvaginitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Vulvovaginitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

